Early Experiences with Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Failed Target Therapy
10.22465/kjuo.2019.17.2.96
- Author:
Jong Hoon LEE
1
;
Minyong KANG
;
Jae Hoon CHUNG
;
Hyun Hwan SUNG
;
Hwang Gyun JEON
;
Byung Chang JEONG
;
Seong Soo JEON
;
Hyun Moo LEE
;
Se Hoon PARK
;
Binnari KIM
;
Ghee Young KWON
;
Seong Il SEO
Author Information
1. Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. seongil.seo@samsung.com
- Publication Type:Original Article
- Keywords:
Metastasis;
Monoclonal antibody;
Programmed cell death 1 ligand 1;
Renal cell carcinoma;
Treatment outcome
- MeSH:
Antigens, CD274;
Carcinoma, Renal Cell;
Cell Death;
Disease-Free Survival;
Humans;
Male;
Neoplasm Metastasis;
Retrospective Studies;
Treatment Outcome
- From:Korean Journal of Urological Oncology
2019;17(2):96-102
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The efficacy of nivolumab in metastatic renal cell carcinoma (mRCC) has been proven. However, the nivolumab experience in Korean patients with mRCC is still poorly reported. We report initial experiences with the efficacy and safety of nivolumab in patients with mRCC. MATERIALS AND METHODS: We retrospectively reviewed records for 25 patients with mRCC who had failed targeted therapy and were treated by nivolumab (2 mg/kg, every 2 weeks) at a single institution. The primary endpoint was objective response rate (ORR), and secondary endpoints were progression-free survival (PFS), safety profiles, and ORR in a programmed cell death receptor ligand 1 (PD-L1) expression subgroup. RESULTS: The median age was 60 years and 16 patients (64%) were male. Objective responses were achieved in 8 patients (32.0%) (complete response, 1; partial response, 7). Median PFS was 3.0 months (95% confidence interval, 1.46–4.53). Treatment-related adverse events (AEs) of any grade were observed in 19 patients (76.0%) with 6 (24.0%) experiencing grade 3 to 4 treatment-related AEs. In subgroups by PD-L1 expression levels classified as 1% or greater and less than 1%, ORR was 50% and 0%, respectively. CONCLUSIONS: This study showed the efficacy and safety of initial experiences with nivolumab in Korean patients with mRCC who had failed targeted therapy. Our results were comparable to recent clinical trials on nivolumab in mRCC.
